山东东营发现一例血清IgG抗体阳性人员 无传染性

2020-04-09 半岛网 半岛网

官方称经专家组综合判定,该人员为既往感染者,已康复,无传染性。

关于东营市一例血清IgG抗体阳性人员

后续情况说明

2020年4月7日,东营市在重点人群健康检查中发现一名来自湖北省核酸检测阴性、血清IgG抗体阳性人员,现将后续有关情况说明如下:

一、4月8日晚,在间隔24小时后再次对该人员标本核酸检测,结果为阴性。

二、经市委疫情防治专家组综合判定,该人员为既往感染者,已康复,无传染性。

东营市卫生健康委

2020年4月8日

相关阅读:东营发现一名新冠病毒IgG抗体阳性人员,情况说明来了

2020年4月7日,东营市在重点人群健康检查中发现一名来自湖北省核酸检测阴性、血清IgG抗体阳性人员,现将有关情况说明如下:

一、新型冠状病毒特异性IgG(免疫球蛋白G)抗体一般在感染后期产生。如果IgG抗体阳性且第一次核酸阴性,需要间隔24小时再次对其核酸检测。若检测结果继续阴性,说明感染过并获得一定免疫保护,根据近期流行病学调查数据,未发现此类人群具有传染性。

二、新冠肺炎确诊病例及无症状感染者的主要判定依据是核酸检测,血清抗体检测一般作为筛查辅助技术,不单独作为确诊病例或无症状感染者的诊断依据。

三、目前,该人员CT、血常规检查均正常,无发热、咳嗽等异常症状。后续情况,将按程序及时发布。

东营市卫生健康委

2020年4月8日

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1948124, encodeId=5a981948124b9, content=<a href='/topic/show?id=3aae55212db' target=_blank style='color:#2F92EE;'>#抗体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55212, encryptionId=3aae55212db, topicName=抗体阳性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Aug 20 19:10:28 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911518, encodeId=ea46191151868, content=<a href='/topic/show?id=77b3259009f' target=_blank style='color:#2F92EE;'>#传染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25900, encryptionId=77b3259009f, topicName=传染性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Thu Oct 08 20:10:28 CST 2020, time=2020-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812190, encodeId=5023181219080, content=<a href='/topic/show?id=d8b38935421' target=_blank style='color:#2F92EE;'>#血清IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89354, encryptionId=d8b38935421, topicName=血清IgG)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Sep 28 08:10:28 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615213, encodeId=e3601615213c9, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sat Apr 11 03:10:28 CST 2020, time=2020-04-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1948124, encodeId=5a981948124b9, content=<a href='/topic/show?id=3aae55212db' target=_blank style='color:#2F92EE;'>#抗体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55212, encryptionId=3aae55212db, topicName=抗体阳性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Aug 20 19:10:28 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911518, encodeId=ea46191151868, content=<a href='/topic/show?id=77b3259009f' target=_blank style='color:#2F92EE;'>#传染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25900, encryptionId=77b3259009f, topicName=传染性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Thu Oct 08 20:10:28 CST 2020, time=2020-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812190, encodeId=5023181219080, content=<a href='/topic/show?id=d8b38935421' target=_blank style='color:#2F92EE;'>#血清IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89354, encryptionId=d8b38935421, topicName=血清IgG)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Sep 28 08:10:28 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615213, encodeId=e3601615213c9, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sat Apr 11 03:10:28 CST 2020, time=2020-04-11, status=1, ipAttribution=)]
    2020-10-08 xzw113
  3. [GetPortalCommentsPageByObjectIdResponse(id=1948124, encodeId=5a981948124b9, content=<a href='/topic/show?id=3aae55212db' target=_blank style='color:#2F92EE;'>#抗体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55212, encryptionId=3aae55212db, topicName=抗体阳性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Aug 20 19:10:28 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911518, encodeId=ea46191151868, content=<a href='/topic/show?id=77b3259009f' target=_blank style='color:#2F92EE;'>#传染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25900, encryptionId=77b3259009f, topicName=传染性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Thu Oct 08 20:10:28 CST 2020, time=2020-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812190, encodeId=5023181219080, content=<a href='/topic/show?id=d8b38935421' target=_blank style='color:#2F92EE;'>#血清IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89354, encryptionId=d8b38935421, topicName=血清IgG)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Sep 28 08:10:28 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615213, encodeId=e3601615213c9, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sat Apr 11 03:10:28 CST 2020, time=2020-04-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1948124, encodeId=5a981948124b9, content=<a href='/topic/show?id=3aae55212db' target=_blank style='color:#2F92EE;'>#抗体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55212, encryptionId=3aae55212db, topicName=抗体阳性)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Thu Aug 20 19:10:28 CST 2020, time=2020-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911518, encodeId=ea46191151868, content=<a href='/topic/show?id=77b3259009f' target=_blank style='color:#2F92EE;'>#传染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25900, encryptionId=77b3259009f, topicName=传染性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Thu Oct 08 20:10:28 CST 2020, time=2020-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1812190, encodeId=5023181219080, content=<a href='/topic/show?id=d8b38935421' target=_blank style='color:#2F92EE;'>#血清IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89354, encryptionId=d8b38935421, topicName=血清IgG)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Sep 28 08:10:28 CST 2020, time=2020-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615213, encodeId=e3601615213c9, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Sat Apr 11 03:10:28 CST 2020, time=2020-04-11, status=1, ipAttribution=)]

相关资讯

Medrxiv:新冠肺炎特异性抗体可长期存在,老年人的含量明显高于年轻人

根据世界卫生组织发布的数据,新冠肺炎疫情已扩散至200个国家和地区,全球确诊病例累计超过100万例,死亡5万余例。随着全球COVID-19大流行的进行,从恢复性血浆患者被认为是预防感染或治疗疾病的有前

为什么德国COVID-19的病死率较低?

近日,纽约时报发表了一篇文章,对德国COVID-19病死率低的原因进行了分析。

新冠肺炎临床研究需要注意的特殊问题6

举国体制抗击新冠肺炎爆发流行取得了阶段性重大成果,疫情得到有效控制,国内的新发病例数已降至个位数,低于输入病例数。在抗击新冠肺炎的斗争中临床研究发挥了重要作用,在诊断、治疗、流行病学等方面获取了一大批

Lancet子刊:全球仅6%的新冠肺炎患者被发现

德国哥廷根大学的Christian Bommer博士和Sebastian Vollmer教授使用了发表在

疫情之下糖尿病患者的窘境

糖尿病患者是新冠肺炎高危人群,需要为他们撑起特殊保护伞。

意大利1591例进入ICU的COVID-19患者的特征和临床结局

近日,JAMA刊登了一篇文章,探讨了意大利伦巴第大区在重症监护病房(ICU)进行治疗的1591例COVID-19患者的特征和结局。